Takeda To Join With Baxter Of U.S. To Produce Bird-Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical and U.S.-based Baxter International have agreed to join in producing influenza vaccines, with a goal of having the first on the Japanese market in fiscal 2012. The agreement involves Takeda licensing Baxter's vaccine-production technology, which involves cell-culture-based production, considered faster and better suited for mass vaccine production. The initial vaccine envisioned is one to protect against the H5N1 bird flu virus, feared capable of becoming an epidemic. (Click here for more - a subscription may be required